Background-CSF analysis is often deferred in patients with cryptococcal disease, particularly in the absence of neurologic manifestations. We sought to determine if a subset of SOT recipients with high likelihood of CNS disease could be identified in whom CSF analysis must be performed.
Introduction
Cryptococcosis is a significant opportunistic mycosis in solid organ transplant (SOT) recipients (1) (2) (3) (4) . Currently, cryptococcal disease is the third most common mycosis following candidiasis and aspergillosis in SOT recipients, representing 9% of the invasive fungal diseases post-transplant (5) . The overall incidence of cryptococcosis in SOT recipients is 1.6% (range: 0.5-4.1%) and central nervous system (CNS) disease accounts for 54-60% of all cryptococcal disease in these patients (3) .
Prompt recognition of CNS disease is critical since it affects management, including the choice and duration of antifungal therapy and necessity of adjunctive therapy for alleviation of elevated intracranial pressure (6) . The mortality rate approaches 30% in SOT recipients with CNS disease compared to 7% in those with cryptococcosis limited to the lungs (3) . Given these prognostic and therapeutic implications, the current practice guidelines of the Infectious Diseases Society of America (IDSA) recommend CSF analysis in all patients with cryptococcosis (6) . In the clinical setting however, CSF analysis is not always performed. Indeed, 14-27% of the non-HIV infected patients with cryptococcosis, including SOT recipients in previous studies did not undergo CSF analysis (7, 8) . Thus, we sought to determine if a subset of SOT recipients with high likelihood of CNS disease could be identified in whom CSF analysis should be considered mandatory.
Materials and Methods
The study population comprised a multicenter cohort of SOT recipients with cryptococcosis at the participating sites. The study was conducted between 2001-07 and a detailed description of this cohort has been published elsewhere (9, 10) . None of the patients were HIV infected. Cryptococcal disease was defined as per the European Organization for Research and Treatment in Cancer and the Mycoses Study Group (EORTC/MSG) criteria (11) . CNS disease was diagnosed based on positive CSF culture or positive cryptococcal antigen in the CSF. Cryptococcal antigen testing was performed as part of standard clinical care at each institution. Variables assessed in this report included demographic characteristics, immunosuppressive regimen at the time of diagnosis, dose of prednisone, time elapsed from transplantation to onset, sites of infection, rejection episodes or retransplantation, renal dysfunction at baseline (defined as creatinine level ≥2.0 mg/dl), cytomegalovirus (CMV) infection and CMV disease, presenting symptoms (abnormal mental status, fever), serum cryptococcal antigen, fungemia, and mortality at 90 days. Serum cryptococcal antigen titer >1:64 was used to create a dichotomous variable since the overall median titer in the study cohort was 1:64. Likewise, late-onset cryptococcosis was considered as the time from transplantation to onset of cryptococcosis >24 months given that this time period approximated the median time to onset of cryptococcal disease in our patients (22 months). Mental status was assessed at presentation and categorized as alert, lethargic, stuporous, or comatose. Level of consciousness other than normal i.e., lethargy, stupor, or coma was considered as abnormal mental status. Only those patients who underwent CSF analysis were included in the study.
Statistical Analyses
Continuous data were compared using Mann-Whitney test. Categorical data were compared using chi-squared test or Fisher's exact test when appropriate. Logistic regression models were constructed to calculate odds ratios (OR) and 95% confidence intervals (CIs) for factors associated with CNS cryptococcosis. Significant factors in univariable analyses (p<0.10) were entered into a multivariable model to assess for the effect of several factors as predictors of CNS disease. For these models, backward selection was used with factors removed at p>0.05. The final model was evaluated using the Hosmer-Lemeshow goodness of fit test. The power of the model's predicted value to discriminate between the presence and absence of CNS disease was estimated using area under the receiver operating characteristic curve. The chi-squared test for trend was used to assess an increase in the risk of CNS disease associated with the number of predictors present. Intercooled Stata (version 10.1, StataCorp) was used for all analyses. A two-tail p<0.05 was considered statistically significant.
Results
A total of 129 (88%) of the 146 SOT recipients underwent CSF analysis of whom 62% (80/129) had CNS cryptococcal disease ( Table 1 ). The diagnosis of CNS disease was based on positive culture in 78% (62/80), and positive cryptococcal antigen in 22% (18/80) of the patients. Baseline characteristics of the patients with and without CNS cryptococcosis are shown in Table 2 . Patients with abnormal mental status and fever at presentation were significantly more likely to have CNS disease ( Table 2) . A significantly greater number of the patients with CNS disease were receiving high-dose prednisone (≥10 mg/day) (p=0.009) and the median dose of prednisone was higher in patients with CNS disease compared to those without CNS disease (p=0.026). Overall, cryptococcosis was diagnosed at a median time of 22 months post-transplant (interquartile range [IQR] 8.0-50 months). Time elapsed from transplantation to the onset of cryptococcosis was a median of 25 months in patients with CNS disease and 17 months in those without CNS disease (p=0.051) ( Figure 1 ) and proportionally fewer patients with calcineurin-inhibitor agent based immunosuppressive regimen had CNS disease (p=0.053) ( Table 2) .
Results of the serum cryptococcal antigen test at the time of diagnosis were available in 98 (76%) of the 129 patients. A higher serum cryptococcal antigen titer correlated with CNS disease; the median titer was 1:512 in the patients with CNS disease as opposed to 1:8 in those without CNS disease (p<0.001). A majority (97%) of the patients with serum cryptococcal antigen titer >1:256 had CNS disease however, negative serum cryptococcal antigen did not appear to exclude CNS disease. Indeed, 11% (2/18) of those with negative serum antigen also had CNS disease. Presence of fungemia also significantly predicted CNS disease (p<0.001). Other variables such as age, gender, type of transplant, T-cell antibody agent use, prior rejection, retransplantation, renal dysfunction at baseline, and CMV infection or disease were not significantly different for patients with and without CNS disease.
A multivariable logistic regression model was constructed to identify predictors of CNS disease in SOT recipients with cryptococcosis as described in the methods. Late-onset cryptococcosis (p=0.009), abnormal mental status (p=0.033), serum cryptococcal antigen titer >1:64 (p=0.001), and fungemia (p=0.024) were significantly associated with CNS disease ( Table 3 ). Prednisone dose, renal dysfunction, immunosuppressive agent, fever, and type of transplant were not statistically significant and were removed from the final model. Since the results of serum cryptococcal antigen test were available in 98/129 (76%) of the patients, another logistic regression model that excluded serum cryptococcal antigen was considered. The same factors i.e., abnormal mental status (OR 16, 95% CI 3.3-78; p=0.001), fungemia (OR 15, 95% CI 2.9-75; p=0.001), late-onset cryptococcosis (OR 4.3, 95% CI 1.7-11; p=0.003) remained significantly associated with CNS disease.
In all, 95% (37/39) of the patients with abnormal mental status had CNS disease. However, 48% (42/88) of those with normal mental status were also diagnosed with CNS disease. Given that abnormal mental status is an obvious sign indicating the need for CSF analysis, we investigated predictors of CNS disease in patients with normal mental status. Serum cryptococcal antigen titer >1:64 (OR 6.3, 95% CI 1.04-38; p=0.045), fungemia (OR 12.9, 95% CI 3.1-54; p<0.001), and late-onset cryptococcosis (OR 6.9, 95% CI 1.7-28; p=0.007) were independently associated with CNS disease in patients with normal mental status. The risk of CNS disease in SOT recipients with cryptococcosis who had normal mental status was 14% if none, 39% if one, and 94% if two of the aforementioned risk factors existed (X 2 for trend p<0.001). The risk of CNS disease in SOT recipients with cryptococcosis is also depicted in a decision-tree fashion (Figure 2 ). The mortality rate at 90 days was 19% (15/80) in patients with CNS disease and 4.1% (2/49) in those without CNS disease (p=0.017).
Patients who did not undergo CSF analysis (n=17) did not differ from those who had CSF analysis performed (n=129) with regards to age, gender, type of transplant, immunosuppressive regimen, time to onset of cryptococcal disease, fungemia, or serum cryptococcal antigen titer (data not shown). Abnormal mental status was documented in 31% (39/127) of the patients who had CSF analysis versus 8.3% (1/12) of those who did not (p=0.18). Overall mortality rate at 90 days was 29% (5/17) in patients who did not have CNS analysis performed.
Discussion
Our prospective, multicenter study provided a unique opportunity to investigate the predictors of CNS disease specifically in SOT recipients. Overall, CNS disease was documented in 62% (80/129); 95% of the patients with cryptococcosis with abnormal mental status had CNS disease as did 48% of those with normal mental status. Serum cryptococcal antigen titer >1:64, fungemia, and onset of cryptococcosis >24 months after transplantation were significantly associated with CNS disease in patients with normal mental status. CNS disease was documented in 94% of the patients with normal mental status if any two of the aforementioned risk factors existed compared to 14% if none of these were present (p<0.001).
It is noteworthy that the patients who developed cryptococcosis >24 months after transplantation were more likely to have CNS disease than those with early-onset cryptococcosis. Two potential explanations exist for this observation. Patients in the late post-transplant period are typically cared for by local providers at sites remote from the transplant centers and subtle manifestations of early disease may not be recognized. Thus, it is possible that infrequent follow-up in the late post-transplant period may lead to delayed presentation with fungal burden reaching high levels before the diagnosis is established. Second, most cryptococcal disease in SOT recipients is considered to result from reactivation of latent infection (12) . We have previously shown that patients with reactivation infection or prior seroreactivity against C. neoformans developed cryptococcal disease significantly earlier post-transplant than those with primary infection or without preexisting antibody (5.6 vs. 40.6 months; p=0.0011) (13) . Thus, the absence of anticryptococcal antibody in the setting of primary infection in the late post-transplant period may lead to greater severity of disease such as dissemination and CNS disease. Indeed, a study in the pre-HIV era showed that the lack of cryptococcal antibody was associated with higher mortality in patients with cryptococcal meningitis (14) . It is therefore plausible that SOT recipients with late-onset cryptococcosis were potentially more likely to develop primary infection with a higher attendant risk of disseminated or CNS disease.
Serum cryptococcal antigen >1:64 and fungemia are indicative of higher fungal burden and their association with CNS disease is therefore intuitively understandable. CSF cryptococcal antigen titers have been shown to correlate with inoculum size or cryptococcal colonyforming unit counts in the CSF (15) . Positive serum cryptococcal antigen has also been associated with disseminated (7, 10) or more severe diseases (16) (17) (18) . We have previously shown that serum cryptococcal antigen positivity in SOT recipients with pulmonary cryptococcosis correlated with extrapulmonary as well as more advanced radiographic disease (10) . Moreover, serum cryptococcal antigen titer ≥1:64 was associated with disseminated disease in HIV-negative patients with pulmonary cryptococcosis (7) . Fungemia likewise is an evidence for dissemination and severity of disease (17, 18) . Indeed, 94% (29/31) of our patients with fungemia had CNS disease.
Precise reasons why CSF analysis is often deferred in patients with cryptococcosis are not fully understood. CSF analysis is an invasive procedure and the absence of overt CNS manifestations, perception that CSF analysis may not alter antifungal therapeutic plan, or relative contraindications to lumbar puncture, such as coagulopathy may preclude routine performance of this procedure in all patients. It should however, be noted that CSF analysis is critical not only for the diagnosis of CNS disease, but also for the assessment of intracranial pressure. The implications of measuring intracranial pressure were underscored by a recent study that evaluated adherence to the IDSA guidelines in patients with cryptococcosis (19) . Of 14 of 26 patients (54%) who did not comply with the proposed guidelines, including assessment of the CSF opening pressure and/or measures to lower elevated intracranial pressure, 50% (7/14) developed new cranial nerve deficits or visual and auditory dysfunction (19) .
Currently, a polyene (i.e., amphotericin B deoxycholate or lipid formulations of amphotericin B) is recommended for the treatment of CNS cryptococcosis in SOT recipients whereas mild to moderate cryptococcosis limited to the lungs can be treated with fluconazole (1, 20, 21) . It may be argued that CSF analysis is expendable if a polyene is employed for the treatment of cryptococcosis in these patients. In this context, our group has recently shown that lipid formulations of amphotericin B appear to be associated with better outcome when compared to amphotericin B deoxycholate in SOT recipients with CNS cryptococcosis (22) . Thus, CSF analysis may influence not only the class of antifungal agent but the type of polyene employed for the treatment of cryptococcosis.
Certain limitations of our study deserve to be acknowledged. A total of 12% (17/146) of the patients were excluded from this study because CSF analysis was not performed. While the precise reasons are not known, we speculate that lack of neurological symptoms in these patients may be the main reason for deferring CSF analysis. Ideally, our model identifying predictors of CNS disease should be confirmed in a validation study. That having been said, larger studies to validate these observations may be challenging, if not logistically infeasible given a relatively low frequency of cryptococcosis in SOT recipients.
In summary, we have identified readily assessable, previously unrecognized predictors of CNS disease in SOT recipients with cryptococcosis. While CSF analysis should be routinely performed in all patients with cryptococcosis, it should be a particular consideration in patients with serum cryptococcal antigen titer >1:64, fungemia, abnormal mental status, and development of cryptococcosis more than 24 months after transplantation. Risk of central nervous system disease in solid organ transplant recipients with cryptococcosis. The denominators depict the number of patients with data available in each cell. 
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